These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2690 related items for PubMed ID: 795538

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
    Perry MC, Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG.
    Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Ahmann DL, O'Connell MJ, Bisel HF, Edmonson JH, Hahn RG, Frytak S.
    Cancer Treat Rep; 1977 Sep; 61(1):81-2. PubMed ID: 324622
    [No Abstract] [Full Text] [Related]

  • 7. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, O'Connell MJ, Frytak S.
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract] [Full Text] [Related]

  • 8. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM.
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
    Eagan RT, Ames MM, Powis G, Kovach JS.
    Cancer Treat Rep; 1982 Feb; 66(2):283-7. PubMed ID: 7034934
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 14. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
    Schilcher RB, Haas CD, Samson MK, Young JD, Baker LH.
    Cancer Res; 1986 Jun 15; 46(6):3147-51. PubMed ID: 3698029
    [Abstract] [Full Text] [Related]

  • 15. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, Bernareggi A, Camboni G, Armand JP.
    Clin Cancer Res; 2001 Jan 15; 7(1):43-50. PubMed ID: 11205916
    [Abstract] [Full Text] [Related]

  • 16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 15; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
    Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M, Rouesse J, Banzet P, Jacquillat C.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6782-5. PubMed ID: 3677107
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 135.